MeSH term
Frequency | Condition_Probility | Adolescent | 11 | 0.0 |
Adult | 22 | 0.0 |
Aged | 10 | 0.0 |
Child | 11 | 0.0 |
Female | 26 | 0.0 |
Glycogen/metabolism | 9 | 18.0 |
Humans | 91 | 0.0 |
Male | 26 | 0.0 |
Middle Aged | 10 | 0.0 |
Mutation | 6 | 0.0 |
Pedigree | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 59 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
Base Sequence | 21 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cell Line | 10 | 0.0 |
DNA Primers | 3 | 0.0 |
alpha-Glucosidases/*genetics/metabolism | 4 | 66.0 |
Animals | 27 | 0.0 |
Dependovirus/*genetics | 2 | 2.0 |
Disease Models, Animal | 8 | 0.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Glycogen Storage Disease Type II/enzymology/genetics/*therapy | 2 | 100.0 |
Homozygote | 4 | 0.0 |
Infant | 11 | 0.0 |
Mice | 17 | 0.0 |
Mice, Knockout | 10 | 0.0 |
Myocardium/metabolism | 4 | 1.0 |
Transduction, Genetic | 4 | 1.0 |
Glucan 1,4-alpha-Glucosidase/*genetics | 4 | 66.0 |
Muscle, Skeletal/*metabolism | 2 | 1.0 |
DNA Mutational Analysis | 5 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Glucan 1,4-alpha-Glucosidase/deficiency/*genetics | 3 | 100.0 |
Age of Onset | 8 | 0.0 |
Disease Progression | 3 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Nuclear Family | 2 | 0.0 |
Phenotype | 17 | 0.0 |
Trinucleotide Repeat Expansion/*genetics | 3 | 5.0 |
Mice, Transgenic | 4 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Child, Preschool | 5 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Reference Values | 5 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Blotting, Western | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
*Gene Transfer Techniques | 5 | 1.0 |
Genetic Vectors | 3 | 0.0 |
Lysosomes/metabolism | 2 | 1.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Time Factors | 6 | 0.0 |
Age Factors | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 5 | 0.0 |
Adenoviridae/genetics | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Receptor, IGF Type 2/metabolism | 2 | 9.0 |
alpha-Glucosidases/*genetics | 13 | 68.0 |
*Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Trinucleotide Repeats/*genetics | 2 | 2.0 |
Islets of Langerhans/*immunology | 2 | 5.0 |
Protein-Tyrosine-Phosphatase/immunology | 2 | 25.0 |
France | 2 | 0.0 |
Genotype | 10 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Friedreich Ataxia/*genetics | 5 | 55.0 |
Heterozygote | 4 | 0.0 |
Gene Therapy/methods | 2 | 2.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
*Gene Expression | 2 | 0.0 |
*Iron-Binding Proteins | 6 | 15.0 |
Phosphotransferases (Alcohol Group Acceptor)/*genetics | 4 | 12.0 |
Alleles | 12 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Glycogen Storage Disease Type II/enzymology/*genetics | 5 | 83.0 |
Introns/genetics | 2 | 0.0 |
Lysosomes/enzymology | 4 | 6.0 |
Point Mutation | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Iron-Binding Proteins/*genetics | 2 | 66.0 |
Molecular Sequence Data | 20 | 0.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Glycogen Storage Disease Type II/genetics/*therapy | 2 | 100.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Glycogen Storage Disease Type II/*genetics | 11 | 84.0 |
Electromyography | 2 | 1.0 |
Leukocytes/enzymology | 2 | 1.0 |
Comparative Study | 7 | 0.0 |
Friedreich Ataxia/epidemiology/*genetics | 2 | 100.0 |
Gene Frequency | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Japan | 2 | 0.0 |
*Mutation | 11 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Introns | 3 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
*Trinucleotide Repeats | 3 | 2.0 |
Exons | 6 | 0.0 |
Lysosomes/*enzymology | 3 | 6.0 |
Action Potentials/physiology | 2 | 4.0 |
English Abstract | 2 | 0.0 |
Rats | 3 | 0.0 |
Glycogen Storage Disease Type II/therapy | 2 | 100.0 |
DNA | 2 | 0.0 |
Polymorphism, Genetic | 6 | 0.0 |
Sequence Analysis | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
*RNA Splicing | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Fibroblasts | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Point Mutation/*genetics | 2 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Exons | 2 | 0.0 |
Glucosidases/*genetics | 6 | 46.0 |
Thymidine Kinase/*genetics | 2 | 4.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Glucan 1,4-alpha-Glucosidase/*genetics/metabolism | 2 | 66.0 |
Blotting, Southern | 4 | 0.0 |
Deoxyribonucleases, Type II Site-Specific | 5 | 1.0 |
Restriction Mapping | 4 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Chromosome Banding | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Health Care Costs | 2 | 7.0 |
Hospitalization/*economics | 2 | 28.0 |
Medicare/*economics | 2 | 22.0 |
*Pharmacy Service, Hospital | 2 | 33.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Glycine/*analogs & derivatives/metabolism | 2 | 50.0 |
Glycine/*analogs & derivatives/urine | 2 | 50.0 |
alpha-Glucosidases/deficiency/*genetics | 2 | 100.0 |
DNA Probes | 3 | 0.0 |
*Genes, Structural | 6 | 0.0 |
*Chromosomes, Human, Pair 17 | 4 | 0.0 |
Taq Polymerase | 2 | 5.0 |
Electrophoresis, Starch Gel | 3 | 2.0 |
Glycogen/*metabolism | 2 | 14.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Immunoelectrophoresis | 2 | 0.0 |
*Chromosomes, Human, 16-18 | 3 | 15.0 |
Genes, Structural | 3 | 0.0 |
